Climb Bio, Inc. (CLYM) Financial Analysis & Valuation | Quarter Chart
Climb Bio, Inc. (CLYM)
CLYMPrice: $6.77
Fair Value: 🔒
🔒score
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and me... more
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven infl... more
Description
Shares
| Market Cap | $461.61M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Aoife Brennan BCh MMSc |
| IPO Date | 2021-08-10 | CAGR | — |
| Employees | 17 | Website | eliemtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CLYM chart loading...
Fundamentals
Technicals
| Enterprise Value | $234.33M | P/E Ratio | -6.46 |
| Forward P/E | -5.51 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.84 |
| P/CF Ratio | -8.39 | P/FCF Ratio | -8.46 |
| EPS | $-0.59 | EPS Growth 1Y | -58.24% |
| EPS Growth 3Y | -48.26% | EPS Growth 5Y | -52.66% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.33% | ROA | -0.36% |
| ROCE | -0.42% | Current Ratio | 15.16 |
| Quick Ratio | 15.16 | Cash Ratio | 5.11 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 34.66 | Piotroski Score | 1 |